CNS Pharmaceuticals, Inc. — FY 2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019. The company filed as a small, development-stage oncology pharmaceutical company; its common stock began trading on Nasdaq under CNSP in November 2019.
Business context and development
The company’s primary program is Berubicin, an investigational anthracycline for glioblastoma. Reata’s earlier Phase 1 IND is no longer active, so CNS must obtain a new IND before conducting further trials. Management planned to propose a multicenter Phase 2 study in recurrent or progressive glioblastoma, but the proposed design was not final or FDA-approved at the filing date.
Historical Reata Phase 1 results were limited: 54 patients received Berubicin; among 25 evaluable patients in Group A, one had a complete response, one an unconfirmed partial response, and 10 stable disease. All seven evaluable Group C patients had progressive disease. The company cautioned that these early results do not establish later-stage efficacy. In January 2020, it also licensed UTMDACC technology related to WP1244, subject to fees, milestones, royalties, and diligence requirements.
Financial results and liquidity
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Revenue | None | None |
| General and administrative expense | $1.979 million | $0.861 million |
| Research and development expense | $1.854 million | $0.021 million |
| Total operating expenses | $3.833 million | $0.882 million |
| Net loss | $3.877 million | $7.392 million |
| Basic and diluted loss per share | $0.28 | $0.70 |
| Net cash used in operating activities | $3.553 million | $0.716 million |
The lower net loss versus 2018 largely reflects the absence of a $6.287 million loss on settlement of convertible debt recorded in 2018; operating expenses increased in 2019. R&D spending rose substantially, mainly for patent maintenance and contract work preparing for a Phase II study. No profit or operating margin was reported because the company had no product revenue.
At December 31, 2019, cash and cash equivalents were $7.241 million, working capital was $7.583 million, total assets were $7.912 million, total liabilities were $0.311 million, and stockholders’ equity was $7.601 million. No notes, convertible notes, or SAFE liabilities remained on the year-end balance sheet. Financing activities provided $10.260 million in 2019, including $10.295 million of net proceeds from common-stock issuance; the IPO and over-allotment accounted for approximately $8.787 million net proceeds.
Material changes, outlook, and risks
- The November 2019 IPO materially strengthened liquidity and converted outstanding convertible notes and SAFE agreements into common shares. Management said the IPO resolved previously disclosed substantial doubt about going concern, but expected continued operating losses and negative operating cash flows.
- Management estimated it would need approximately $7 million of additional financing to complete the Berubicin Phase 2 trial and approximately $2 million for near-term WP1244 preclinical work, plus operating working capital. It had no commitment for this funding and warned that failure to raise capital could force delays, reduced spending, or a scaled-back plan. The filing estimated year-end cash would fund planned operations into, but not beyond, calendar 2021.
- Berubicin development, clinical-trial execution, FDA approval, financing, and eventual commercialization are uncertain. The company relies on third-party manufacturers, has no sales organization, and faces competition from better-resourced developers. Historical Phase 1 adverse events included hematologic and neurologic events; the filing notes many CNS events may reflect underlying disease and that the listed events were not necessarily drug-related.
- Three licensed U.S. Berubicin patents were stated to expire in March 2020. As of the report, the company had not applied for orphan-drug designation; exclusivity or further patent protection was not assured.
- Related-party matters warrant attention: HPI is affiliated with the controlling shareholder, and WPD and Animal Life Sciences have founder-related ownership connections. The filing also disclosed a material weakness in internal controls—lack of segregation of duties and formal control documentation—and concluded disclosure controls were ineffective. The independent auditor issued an unqualified opinion on the financial statements but did not audit internal-control effectiveness.
- The company reported no pending material legal proceedings. The January 2020 UTMDACC license and March 2020 director-compensation and executive-bonus actions occurred after fiscal year-end.
Key facts for investors to verify
- Whether CNS obtains a new IND and FDA agreement on the Berubicin Phase 2 protocol, and the trial’s start, enrollment, cost, and results.
- Whether additional funding is secured and how long available cash supports operations; compare actual spending with the stated $7 million and $2 million estimates.
- The clinical significance and reproducibility of the historical Phase 1 findings, including safety data and the basis for the reported durable complete response.
- Current patent coverage, any orphan-drug application or designation, and payment and diligence obligations under HPI, WPD, and UTMDACC agreements.
- Progress in remediating the disclosed internal-control material weakness and any subsequent changes in financing, dilution, or related-party arrangements.